Efficacy and safety of mepolizumab in patients with bronchial asthma in real clinical practice


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Persistent eosinophilic inflammation in the mucous membrane of the lower respiratory tract in patients with severe bronchial asthma determines their propensity for an uncontrolled course of the disease against the background of standard pharmacotherapy, and also increases the risk of an unfavorable prognosis, including more frequent and severe exacerbations, emergency care and hospitalizations, the need for high doses inhaled and systemic glucocorticosteroids. Mepolizumab is humanized monoclonal antibody that bind free interleukin-5, as a result of which a pronounced decrease in the number of eosinophils in the blood and respiratory tract is observed. In randomized clinical trials, mepolizumab significantly reduced the frequency of asthma exacerbations and related hospitalizations, reduced the dose of oral glucocorticosteroids, significantly improved the quality of life and control of clinical symptoms, and also improved respiratory function in patients with severe eosinophilic asthma. At the same time, it is difficult to generalize data from controlled studies to the patient population in real life. This review discusses the published results of a number of open-label observational studies on the efficacy and safety of mepolizumab in patients with severe asthma in real clinical practice.

全文:

受限制的访问

作者简介

N. Nenasheva

Russian Medical Academy of Continuous Professional Education

Email: 1444031@gmail.com
Dr. Sci. (Med.), Prof., Head of the Department of Allergology and Immunology 2/1, build. 1, Barrikadnaya str., Moscow 125993, Russian Federation

S. Fedosenko

Siberian State Medical University; GlaxoSmithKline Trading JSC

Tomsk, Russia; Moscow, Russia

E. Barabanova

GlaxoSmithKline Trading JSC

Moscow, Russia

参考

  1. Herland K., Akselsen J.-P., Skjonsberg O., Bjermer L. How representative are clinical study patients with asthma or COPD for a larger «real life» population of patients with obstructive lung disease? Resp Med. 2005;99:11-9. doi: 10.1016/j.rmed.2004.03.026
  2. GINA. Global Strategy for Asthma Management and Prevention. 2020; URL: http://ginasthma.org/2017-gina-report-global-strategy-for-asthma-management-and-prevention/. Accessed: May 29, 2020.
  3. Chung K.F., et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. ERJ. 2014;43:343-73. doi: 10.1183/09031936.00202013.
  4. Tran T.N., et al. Overlap of atopic, eosinophilic, and TH2-high asthma phenotypes in a general population with current asthma. Ann Allergy Asthma Immunol. 2016;116(1):37-42. Doi: 10.1016/j. anai.2015.10.027.
  5. De Groot J., et al. Clinical profile of patients with adult-onset eosinophilic asthma. Eur Respire J Open Res. 2016;2:1-8.
  6. Price D.B., et al. Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. Lancet. Respir Med. 2015;3(11):849-58. Doi: 10.1016/ S2213-2600(15)00367-7.
  7. Rosenberg H.F., Phipps S., Foster P.S. Eosinophil trafficking in allergy and asthma. J Allergy Clin Immunol. 2007;119:1303-10. Doi: 10.1016/j. jaci.2007.03.048.
  8. Nussbaum J.C., et al. Type 2 innate lymphoid cells control eosinophil homeostasis. Nature. 2013;502(7470):245-48. doi: 10.1038/nature12526.
  9. Ortega H.G., et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371:1198-207. Doi: 10.1056/ NEJMoa1403290.
  10. Chupp G.L., et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet. Respir Med. 2017;5:390-400.
  11. Bel E.H., et al. Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma. N Engl J Med. 2014;371:1189-97. doi: 10.1056/NEJMoa1403291.
  12. Albers F.C., Licskai C., Chanez P, et al. Baseline blood eosinophil count as a predictor of treatment response to the licensed dose of mepolizumab in severe eosinophilic asthma. Respir Med. 2019;159:105806. doi: 10.1016/j.rmed.2019.105806.
  13. Humbert M., Albers F.C., Bratton D.J., et al. Effect of mepolizumab in severe eosinophilic asthma according to omalizumab eligibility. Respir Med. 2019;154:69-75. doi: 10.1016/j.rmed.2019.06.004.
  14. Shrimanker R., Keene O., Hynes G., et al. Prognostic and Predictive Value of Blood Eosinophil Count, Fractional Exhaled Nitric Oxide, and Their Combination in Severe Asthma: A Post Hoc Analysis. Am J Respir Crit Care Med. 2019;200(10):1308-12. Doi: 10.1164/ rccm.201903-0599LE.
  15. Chapman K.R., Albers F.C., Chipps B., et al. The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma. Allergy. 2019;74(9):1716-26. doi: 10.1111/all.13850.
  16. Bagnasco D., Caminati M., Passalacqua G. Biologicals for severe asthma: what we can learn from real-life experiences? Curr Opin Allergy Clin Immunol. 2020;20(1):64-70. Doi: 10.1097/ ACI.0000000000000600.
  17. Drick N., et al. Anti-IL-5 therapy in patients with severe eosinophilic asthma - clinical efficacy and possible criteria for treatment response. BMC. Pulm Med. 2018;18(1):119. doi: 10.1186/s12890-018-0689-2.
  18. Pelaia C., et al. Real life of the clinical, functional and hematologic effects of mepolizumab in patients with severe eosinophilic asthma: results of a single-centre observational study. Pulm Pharmacol Ther. 2018;53:1-5. doi: 10.1016/j.pupt.2018.09.006.
  19. Montero-Perez O., Contreras-Rey M.B., Sanchez-Gomez E. Effectiveness and safety of mepolizumab in severe refractory eosinophilic asthma: results in clinical practice. Drugs Context. 2019;8:212584. Doi: 10.7573/ dic.212584.
  20. Kurosawa M., Sutoh E. Prospective open-label study of 48-week subcutaneous administration of mepolizumab in Japanese patients with severe eosinophilic asthma. J Investig Allergol Clin Immunol. 2019;29(1):40-5. doi: 10.18176/jiaci.0285.
  21. Llanos J.-P, et al. Real-World Effectiveness of Mepolizumab in Patients with Severe Asthma: An Examination of Exacerbations and Costs. J Asthma Allerg. 2020;13:77-87. doi: 10.2147/JAA.S236609.
  22. Harvey E.S., et al. Mepolizumab effectiveness and identification of super-responders in severe asthma. Eur Respir J. 2020;55:1902420. doi: 10.1183/13993003.02420-2019.
  23. Taille С., еt al. Mepolizumab in a population with severe eosinophilic asthma and corticosteroid dependence: results from a French early access programme. Eur Respir J. 2020,1902345. doi: 10.1183/13993003.02345-2019.
  24. Caminati M., et al. Mepolizumab for severe eosinophilic asthma: a real-world snapshot on clinical markers and timing of response. Exp Rev Respir Med. 2019;13(12):1205-12. doi: 10.1080/17476348.2019.1676734.
  25. Pelaia C., et al. Real-life evaluation of mepolizumab efficacy in patients with severe eosinophilic asthma, according to atopic trait and allergic phenotype. Clin Exp Allergy. 2020;50(7):780-788. Doi: 10.1111/ cea.13613.
  26. Schleich F., et al. Real-word experience with mepolizumab: Does it deliver what it has promised? Clin Exp Allergy. 2020;50:687-95. doi: 10.1111/cea.13601.
  27. Pertzov B., et al. Efficacy and safety of mepolizumab in a real-world cohort of patients with severe eosinophilic asthma. J Asthma. 2019 Sep 3;1-6. doi: 10.1080/02770903.2019.1658208.
  28. Kavanagh J., et al. Real-World Effectiveness and the Characteristics of a 'Super-Responder' to Mepolizumab in Severe Eosinophilic Asthma. Chest. 2020;158(2):491-500. doi: 10.1016/j.chest.2020.03.042.
  29. Van Toor J.J., et al., Mepolizumab add-on therapy in a real world cohort of patients with severe eosinophilic asthma: response rate, effectiveness, and safety. J Asthma. 2020 Feb 12;1-8. doi: 10.1080/02770903.2020.1723623.
  30. Bagnasco D., et al. One year of mepolizumab. Efficacy and safety in real-life in Italy. Pulm Pharmacol Ther. 2019;58:101836. doi: 10.1016/j.pupt. 2019.101836.
  31. Lombardi C., et al. Analysis of the drop-out rate in patients receiving mepolizumab for severe asthma in real life. Pulm Pharmacol Ther. 2019;54:87-9. doi: 10.1016/j.pupt.2018.12.003.

补充文件

附件文件
动作
1. JATS XML
下载
##common.cookie##